The pledge of \u00a33 million investment by the Medical Research Council towards a translational accelerator will enable the MND community to work in partnership with Dementias Platform UK and the UK Dementia Research Institute.
Oxford University researchers have recently established that laboratory models of Alzheimer\u2019s can reflect in-life clinical symptoms. The team found that nerve cells created in the laboratory from Alzheimer\u2019s disease stem cells reacted to amyloid proteins in a similar way in which the brains of the same Alzheimer\u2019s disease patients reacted to high amyloid protein burden load.
After six years in his role, Prof De Strooper will now return full time to focus on his research on Alzheimer\u2019s disease. DPUK is delighted that he and his lab will continue to work towards translational neuroscience and dementia research.
Dementias Platform UK (DPUK) today launches its new \u2018Data Landscape Report\u2019 \u2013 the most comprehensive overview to date of available dementia data assets worldwide.
New research reveals the association between cumulative life course adversity, depression, and cognitive performance. The findings are published in the scientific journal Nature Scientific Reports.
The UK government has announced the launch of a \u2018national mission\u2019 to tackle dementia, pledging again to double research funding to \u00a3160m per year by 2024.
Diadem SpA, a company developing AlzoSure Predict, the first blood-based test for the early prediction of progression to Alzheimer\u2019s disease, has joined DPUK as an industry partner.
A new study in the DPUK Data Portal has found that social and lifestyle factors \u2013 such as education, income and physical activity \u2013 have a direct effect on cognitive performance. The researchers also showed that late-life lifestyle factors may help preserve cognitive function indirectly by reducing the degeneration of brain cells.
Our circumstances and experiences in childhood can have lasting consequences for our thinking skills, according to a new study funded by Dementias Platform UK.
DPUK\u2019s Great Minds register gives researchers access to more than 6,800 well-characterised volunteers who are ready and willing to take part in dementia studies.
A large-scale analysis of two UK datasets has shown that recurrent depression affects performance in several tests of thinking skills. However, this difference was not altered by taking anti-inflammatory medications such as Ibuprofen, suggesting that neuroinflammation may not be the underlying process driving depression\u2019s effect on cognition.
Researcher Dr Jodi Watt is to examine thousands of magnetic resonance imaging (MRI) brain scans to identify patterns of brain health. Based at the Glasgow Royal Infirmary, Dr Watt will be using the UK Biobank Cohort and the European Prevention of Alzheimer\u2019s Dementia (EPAD) cohort for her exciting postdoctoral project.
DPUK Director Professor John Gallacher has co-signed an open letter to the UK prime minister, published by the Sunday Times, calling for greater investment in dementia research, taking inspiration from the COVID-19 vaccines effort.
A new study by a DPUK-funded researcher has provided evidence that cognitive frailty is a feature of unhealthy yet normal ageing, rather than a sign of impending dementia.
A team of researchers has developed the first model for prescribing personalised medication to treat dementia. The model uses artificial intelligence (AI) to determine the most effective dementia medication for an individual based on factors such as their age, sex, and memory assessment scores.
A new study co-authored by a DPUK-funded researcher has found that people with type-2 diabetes have worse overall brain health than people with high blood pressure, and that those with both conditions have even poorer brain health.
A new study has found that hearing loss increases the risk of a precursor to dementia called mild cognitive impairment \u2013 but this increased risk is not present in people who wear hearing aids.
Previous research has found an inconsistent relationship with dementia and benzodiazepines \u2013 a group of sedative drugs used to treat conditions such as anxiety and insomnia. Now, using the DPUK Data Portal, a team of researchers in France has investigated the association further and found compelling evidence that benzodiazepines reduce some of the hallmarks of Alzheimer\u2019s disease.
![\"\"](\"https://www.dementiasplatform.uk/news-and-media/latest-news/dpuk-welcomes-government2019s-ps50m-investment-in-mnd-research/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n